Boehringer Ingelheim Corporation and Eli Lilly and Company Present Efficacy and Safety Data on Linagliptin and Investigational Compound Empagliflozin* in Various Diabetes Subpopulations
Published: Sep 17, 2013
INGELHEIM, Germany & INDIANAPOLIS, Ind.--(BUSINESS WIRE)-- Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.
Help employers find you! Check out all the jobs and post your resume.